Immutep Limited (ASX: $IMM) Phase I Study Announcement

Immutep Limited (ASX: $IMM) has successfully dosed the first participant in the first-in-human Phase I trial of IMP761, a first-in-class agonist LAG-3 antibody. IMP761 is designed to enhance the 'brake' function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases. The safety data from this study is expected by year-end, with pharmacokinetics and pharmacodynamics data anticipated in the first half of CY2025.

Executive Commentary on IMP761 Phase I Study

IMP761 represents a significant advancement in our efforts to develop novel LAG-3 immunotherapies for cancer and autoimmune diseases. We are encouraged by the potential of IMP761 to restore balance to the immune system and address the underlying cause of autoimmune diseases. The initiation of the Phase I trial marks a crucial milestone in our clinical development program, and we look forward to the safety data expected by year-end and the subsequent assessment of PK/PD relationships in the first half of CY2025.

Summary of Immutep's Phase I Study Announcement

Immutep (ASX: $IMM) has initiated the first-in-human Phase I trial of IMP761, a first-in-class agonist LAG-3 antibody designed to restore balance to the immune system and address the underlying cause of many autoimmune diseases. The safety data from this study is expected by year-end, with pharmacokinetics and pharmacodynamics data anticipated in the first half of CY2025. IMP761 has shown promising results in preclinical studies, demonstrating its effectiveness in suppressing antigen-specific T cell-mediated immune responses. Immutep aims to leverage its expertise to bring innovative treatment options to patients in need and maximize value for shareholders.